![Surviving-an-FDA-GCP-Inspection-500.jpg Surviving an FDA GCP Inspection](https://www.centerwatch.com/ext/resources/products/Surviving-an-FDA-GCP-Inspection-500.jpg?height=200&t=1605810958&width=200)
Home » Pipeline
Pipeline
August 27, 2018
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Aravive Biologics, Inc. | AVB-S6-500 | Platinum-resistant ovarian cancer | Granted Fast Track Designation by the FDA |
Biohaven Pharma | BHV-0223 | Social anxiety and public speaking anxiety disorders | Positive data from a proof-of-concept Phase III clinical trial |
Sun Pharmaceutical Industries Ltd. | Cequa (cyclosporine ophthalmic solution) 0.09 percent | Keratoconjunctivitis sicca (dry eye) | Approval granted by FDA |
Lion TCR Pte. Ltd. | LioCyx™ | Relapsed liver cancer post-liver transplantation | Approval granted by Health Sciences Authority (HSA), Singapore, for multicenter Phase I/II clinical trial |
Taiwan Liposome Company, Ltd. | TLC590, a proprietary BioSeizer™ liposomal formulation of ropivacaine | Postsurgical pain | Dosing of first patients in a Phase I/II trial |
Teva Pharmaceuticals | Generic version of EpiPen Auto-Injector | Severe allergic reactions | Approval granted by the FDA |
BeiGene Ltd. | Tislelizumab, an investigational anti-PD-1antibody, combined with chemotherapy as a potential first-line treatment | Stage IIIB or IV squamous non-small cell lung cancer (NSCLC) | Phase III clinical trial initiated |
Eiger BioPharmaceuticals, Inc. | Avexitide (formerly exendin 9-39) | Post-bariatric surgical patients who experience post-bariatric hypoglycemia (PBH) | Completion of enrollment in Phase II clinical trial |
Escalier Biosciences, BV | ESR-114 topical gel | Mild-to-moderate psoriasis | Phase I/IIa clinical trial initiated |
Sangamo Therapeutics, Inc. | SB-525, a cDNA gene therapy candidate | Hemophilia A | Positive preliminary data from the Phase I/II clinical trial |
ADC Therapeutics | ADCT-402 (loncastuximab tesirine) | Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) | Phase II clinical trial initiated |
Alexion Pharmaceuticals, Inc. | ALXN1210, investigational long-acting C5 complement inhibitor | Paroxysmal nocturnal hemoglobinuria (PNH) | FDA accepted Biologics License Application (BLA) for approval |
Merck & Co. | Keytruda in combination with Alimta (pemetrexed) and platinum chemotherapy as first-line treatment | Metastatic non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations | Granted approval by the FDA |
SPR Therapeutics | SPRING endura (single lead) and extensa (dual lead) Peripheral Nerve Stimulation (PNS) Systems | Pain | Cleared by the FDA |
Univision 360 | Luminelle DTx Hysteroscopy System | Hysteroscopy and cystoscopy | Received 510(k) clearance from the FDA |
Tolero Pharmaceuticals, Inc. | Combination therapy with AbbVie’s venetoclax and Tolero’s investigational agent | Relapsed/refractory acute myeloid leukemia (AML) | Tolero Pharmaceuticals and AbbVie partner for trial |
Upcoming Events
-
21Oct